AbbVie Forms $745M Deal with Haisco for Pain Therapy Development
AbbVie has entered a deal with Haisco to develop pain therapy, with potential value of up to $745M. The agreement follows CollPlant's partnership cut-short in a related move.
AbbVie has formed a significant partnership with Haisco, announcing a deal worth up to $745 million focused on pain therapy development.
This news marks a notable move for AbbVie, as the company looks to strengthen its foothold in the pain management sector.
However, a separate development saw CollPlant, previously a partner, announce the termination of a development agreement with AbbVie. Alongside this move, CollPlant cut its workforce by 50%. The exact cause or impact of AbbVie's deal with Haisco on CollPlant's position remains unclear.
Regardless, the AbbVie-Haisco agreement highlights AbbVie's commitment to innovative treatments and strategic partnerships in the pharmaceutical sector.
Powered by SentiSense - Intelligent Market Analysis